Ananda Pharma

Gain a direct line to Ananda Pharma leadership as we continue our journey to bring MRX1 to market.


Why Invest

Home

Aquis Rule 4.14

Corporate Governance

Company and Advisors

Announcements

Broker Coverage

Publications

Directors

New investors

Presentations

Webinars

Updates

News

Ubuntu

Ananda Pharma investor hub

Read the Article Here

I wrote an article for the Business of Cannabis, which you may find interesting. In it, I argue that with the right investment and policy support, the UK is uniquely positioned to build a world-class cannabis biopharmaceutical ecosystem—one that delivers life-changing therapies to patients while driving significant economic growth.  I believe that Ananda has the potential to lead this movement and become the next GW Pharmaceuticals, a company with a billion dollar drug that achieved incredible returns for shareholders who were prepared to buy into the vision of a licensed CBD drug.

I hope my points resonate. As always, you can put your questions and comments to me alongside this update, I look forward to hearing from you.

The UK Risks Missing Out on the Next $1 Billion Cannabinoid Opportunity